🇨🇦 From April 16-19 we’re in the Canadian Association of Radiologists (CAR) Annual Scientific Meeting in Le Westin Montreal. This year’s theme — 𝘚𝘦𝘦𝘪𝘯𝘨 𝘞𝘩𝘢𝘵 𝘔𝘢𝘵𝘵𝘦𝘳𝘴: 𝘋𝘳𝘪𝘷𝘪𝘯𝘨 𝘊𝘢𝘯𝘢𝘥𝘪𝘢𝘯 𝘙𝘢𝘥𝘪𝘰𝘭𝘰𝘨𝘺 𝘍𝘰𝘳𝘸𝘢𝘳𝘥 — reflects exactly what we’re building at Quibim: improving cancer detection through AI-powered imaging biomarkers and advancing a fully connected prostate ecosystem, from acquisition to diagnosis. Visit us at Booth 12 to explore what’s next in radiology. Niles Geminiuc Joshua Moss Emmanuel Loubet Nathan Clark Edward Ramirez R.T. (R)(MR) B.S. ----- 🇨🇦 Du 16 au 19 avril, nous sommes présents au congrès scientifique annuel de l'Association Canadienne des Radiologistes (ACR) au Westin Montréal. Le thème de cette année — 𝘝𝘰𝘪𝘳 𝘤𝘦 𝘲𝘶𝘪 𝘤𝘰𝘮𝘱𝘵𝘦 : 𝘧𝘢𝘪𝘳𝘦 𝘱𝘳𝘰𝘨𝘳𝘦𝘴𝘴𝘦𝘳 𝘭𝘢 𝘳𝘢𝘥𝘪𝘰𝘭𝘰𝘨𝘪𝘦 𝘤𝘢𝘯𝘢𝘥𝘪𝘦𝘯𝘯𝘦 — reflète pleinement la mission de Quibim : améliorer le dépistage du cancer grâce à des biomarqueurs d’imagerie basés sur l’IA, et faire évoluer un écosystème de la prostate entièrement connecté, de l’acquisition à l’interprétation. Venez nous rencontrer au stand n°12 pour découvrir les prochaines avancées de la radiologie. #CARASM #Radiology #AIinHealthcare #MedicalImaging
We’re excited to partner with deepc to bring QP-Prostate® to the deepcOS® platform. Together, we’re advancing AI-driven prostate imaging to improve diagnostic confidence and support better patient outcomes. #AIinHealthcare #MedicalImaging #AI
🇮🇹 The Associazione Urologi Italiani AURO.it Congress in Genova brings together the Italian urology community to discuss the latest advances shaping the future of this specialty. Visit Fabio Maggioni and Andrea Lorenzo Polo to discover how solutions like QP-Prostate help optimize prostate MRI analysis by reducing inter-reader variability, increasing confidence levels, and supporting more accurate targeting in fusion biopsy procedures. We’d love to connect and exchange views on the future of imaging techniques in urology! #Urology #AIinHealthcare #MedicalImaging
Quibim’s AI-powered imaging biomarkers are already helping pharmaceutical companies predict treatment response, optimize clinical trial selection, stratify risk, and accelerate drug development. With Itta MacNevin joining as Chief Business Officer, we’re ready to go even further. Strengthening our leadership in life sciences marks a key step as we expand our capabilities and support partners in delivering faster, more precise, and more efficient therapies across oncology, immunology, and neurology. Welcome, Itta! https://bit.ly/3OsR0FV #LifeSciences #Innovation #Oncology #Immunology #Neurology
Improving oncology endpoints with AI requires more than just innovation: it demands coordination, robust evidence, and genuine collaboration. 📄 In a recently published white paper, we have joined forces with Friends of Cancer Research, as part of the ai.RECIST initiative, to explore the limitations of current standards and the opportunities AI offers to redefine response assessment. As part of this initiative, our technology—designed to detect, quantify, and automatically track lesions over time—will be evaluated in an upcoming study, with the goal of enabling more precise, consistent, and scalable approaches. #AIinHealthcare #MedicalImaging #ClinicalTrials #CancerResearch #LifeSciences
Today is #WorldHealthDay, and it’s time to face an uncomfortable truth: we’re still too late. Half of all cancers are detected at stages 3 or 4. Autoimmune diseases take, on average, between 5 and 7 years to be diagnosed. And what is the cost of waiting? A 250% to 400% increase due to late detection. Today’s medicine reacts. Tomorrow’s medicine anticipates. At Quibim, we are shifting from precision medicine to precision health, where AI is shaping a future where diseases will be detected before they even exist. Joel Stutz #AIinHealthcare #MedicalImaging #DigitalTwin
The future of radiology is being shaped right now at The British Institute of Radiology Congress. Maria Proud , MHA, Francesca Evans, David Eggleton and Emmanuel L. took this opportunity to connect with the radiology community and demonstrate how AI-based imaging biomarkers are helping to optimize workflows, increase diagnostic reliability, and ultimately improve patient outcomes. 📩 Couldn't meet them? Book a demo here: https://bit.ly/3Q3mkeF #BIRAI2026 #AIinHealthcare #Radiology #MedicalImaging
🇩🇪 We are in Potsdam, Germany, for the final consortium meeting of the European FLUTE Project - AI & Prostate Cancer. This event marks the culmination of three years of progress in applying AI to healthcare. FLUTE has brought together leading partners to leverage federated learning and develop high-impact, privacy-preserving AI that improves the detection of clinically significant #ProstateCancer. At Quibim, we have contributed by extracting quantitative imaging biomarkers from prostate MRI scans at three hospitals by using QP-Prostate®. These biomarkers have fed into the AI models developed by Gradiant. We have also partnered with the UPC to generate and validate synthetic prostate images. We are proud to be part of this journey and the impact that will follow. #AIinHealthcare #Radiology #MedicalImaging #Radiomics
"𝘞𝘩𝘦𝘯 𝘸𝘦 𝘳𝘦𝘷𝘪𝘦𝘸 𝘢𝘯 𝘪𝘮𝘢𝘨𝘦 𝘵𝘩𝘢𝘵 𝘢𝘱𝘱𝘦𝘢𝘳𝘴 𝘯𝘰𝘳𝘮𝘢𝘭 𝘢𝘯𝘥 𝘘𝘶𝘪𝘣𝘪𝘮’𝘴 𝘈𝘐 𝘢𝘭𝘴𝘰 𝘤𝘭𝘢𝘴𝘴𝘪𝘧𝘪𝘦𝘴 𝘪𝘵 𝘢𝘴 𝘯𝘰𝘳𝘮𝘢𝘭, 𝘵𝘩𝘦 𝘱𝘳𝘰𝘣𝘢𝘣𝘪𝘭𝘪𝘵𝘺 𝘰𝘧 𝘵𝘩𝘦𝘳𝘦 𝘣𝘦𝘪𝘯𝘨 𝘯𝘰 𝘢𝘣𝘯𝘰𝘳𝘮𝘢𝘭𝘪𝘵𝘪𝘦𝘴 𝘪𝘴 𝘷𝘦𝘳𝘺 𝘩𝘪𝘨𝘩. 𝘖𝘯 𝘵𝘩𝘦 𝘰𝘵𝘩𝘦𝘳 𝘩𝘢𝘯𝘥, 𝘪𝘧 𝘵𝘩𝘦 𝘈𝘐 𝘥𝘦𝘵𝘦𝘤𝘵𝘴 𝘢 𝘭𝘦𝘴𝘪𝘰𝘯 𝘸𝘦 𝘮𝘢𝘺 𝘩𝘢𝘷𝘦 𝘰𝘷𝘦𝘳𝘭𝘰𝘰𝘬𝘦𝘥—𝘴𝘶𝘤𝘩 𝘢𝘴 𝘢 𝘗𝘐-𝘙𝘈𝘋𝘚 3 𝘭𝘦𝘴𝘪𝘰𝘯—𝘪𝘵 𝘨𝘪𝘷𝘦𝘴 𝘶𝘴 𝘢𝘥𝘥𝘦𝘥 𝘤𝘰𝘯𝘧𝘪𝘥𝘦𝘯𝘤𝘦 𝘢𝘯𝘥 𝘱𝘳𝘰𝘷𝘪𝘥𝘦𝘴 𝘢𝘥𝘥𝘪𝘵𝘪𝘰𝘯𝘢𝘭 𝘴𝘶𝘱𝘱𝘰𝘳𝘵 𝘧𝘰𝘳 𝘰𝘶𝘳 𝘢𝘴𝘴𝘦𝘴𝘴𝘮𝘦𝘯𝘵." As Dr. Jeronimo Barrera Ortega states in this interview, early detection and data-driven healthcare are the areas where artificial intelligence can truly make a difference. #ArtificialIntelligence #ProstateCancer #MedicalImaging #HealthcareInnovation
🇵🇷 At the Society of Abdominal Radiology Annual Meeting in Puerto Rico, we’re showcasing how seamless integration is bringing AI closer to daily clinical practice. Visit Edward Ramirez R.T. (R)(MR) B.S. & Joshua Moss to discover how QP-Prostate® integrates directly into DynaCAD Prostate—delivering quantitative insights within the tools radiologists already use, for more efficient workflows and greater diagnostic confidence. #AIinHealthcare #PrecisionMedicine #ProstateCancer
